î
îŒ
î
Biogen Inc
BIIB176.330USD
+1.510+0.86%
çµå€Â 12/24, 13:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
25.87Bæ䟡ç·é¡
16.04çŽè¿12ã¶æPER
î
詳现æ å ± Biogen Inc äŒæ¥å
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Biogen Incã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãBIIB
äŒç€ŸåBiogen Inc
äžå Žæ¥Sep 17, 1991
æé«çµå¶è²¬ä»»è
ãCEOãViehbacher (Christopher A)
åŸæ¥å¡æ°7605
蚌åžçš®é¡Ordinary Share
決ç®ææ«Sep 17
æ¬ç€Ÿæåšå°225 Binney Street
éœåžCAMBRIDGE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·02142
é»è©±çªå·17814642000
ãŠã§ããµã€ãhttps://www.biogen.com/
äŒæ¥ã³ãŒãBIIB
äžå Žæ¥Sep 17, 1991
æé«çµå¶è²¬ä»»è
ãCEOãViehbacher (Christopher A)
Biogen Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+55.38%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+12.13%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+1.19%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+23.75%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-16.53%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
8.42K
+39.19%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
5.77K
-8.22%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
5.47K
+76.33%
Ms. Susan Langer
Ms. Susan Langer
Independent Director
Independent Director
3.79K
+166.90%
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+55.38%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+12.13%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+1.19%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+23.75%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-16.53%
åçå èš³
é貚: USDæŽæ°æå»: Mon, Oct 6
é貚: USDæŽæ°æå»: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
MS product revenues-TYSABRI
839.80M
31.74%
Spinal Muscular Atrophy-SPINRAZA
543.00M
20.53%
MS product revenues-Fumarate
405.90M
15.34%
MS product revenues-Interferon
246.70M
9.33%
Biosimilar product revenues-BENEPALI
112.10M
4.24%
ä»ã®
498.00M
18.82%
å°åå¥USD
äŒç€Ÿå
åç
æ¯ç
United States
1.38B
52.21%
Rest of World
937.60M
35.44%
United states-Revenues from anti-CD20 therapeutic
467.30M
17.66%
Rest of World-Other revenues
244.60M
9.25%
äºæ¥å¥
å°åå¥
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
MS product revenues-TYSABRI
839.80M
31.74%
Spinal Muscular Atrophy-SPINRAZA
543.00M
20.53%
MS product revenues-Fumarate
405.90M
15.34%
MS product revenues-Interferon
246.70M
9.33%
Biosimilar product revenues-BENEPALI
112.10M
4.24%
ä»ã®
498.00M
18.82%
æ ªäž»
æŽæ°æå»: Sun, Nov 16
æŽæ°æå»: Sun, Nov 16
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
ä»ã®
64.59%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
ä»ã®
64.59%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Investment Advisor
52.68%
Investment Advisor/Hedge Fund
26.60%
Hedge Fund
8.04%
Pension Fund
2.94%
Research Firm
2.45%
Sovereign Wealth Fund
1.59%
Bank and Trust
1.59%
Individual Investor
0.17%
Family Office
0.15%
ä»ã®
3.79%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Mon, Dec 8
æŽæ°æå»: Mon, Dec 8
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q4
1994
139.65M
97.81%
+140.37K
2025Q3
2054
139.52M
98.56%
+3.73M
2025Q2
2076
135.78M
99.30%
-133.40K
2025Q1
2125
136.05M
101.20%
-12.08M
2024Q4
2114
138.28M
98.83%
+2.02M
2024Q3
2089
135.94M
98.13%
+100.43K
2024Q2
2100
135.44M
97.85%
-355.51K
2024Q1
2106
135.99M
97.60%
-5.88M
2023Q4
2136
135.17M
94.89%
+4.09M
2023Q3
2150
131.42M
95.94%
-1.80M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
The Vanguard Group, Inc.
17.21M
11.74%
+255.44K
+1.51%
Jun 30, 2025
PRIMECAP Management Company
15.80M
10.78%
-141.14K
-0.89%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.19M
5.59%
-504.36K
-5.80%
Jun 30, 2025
State Street Investment Management (US)
7.47M
5.09%
+71.90K
+0.97%
Jun 30, 2025
Wellington Management Company, LLP
4.80M
3.27%
+125.98K
+2.70%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.92M
2.67%
+71.29K
+1.85%
Jun 30, 2025
Point72 Asset Management, L.P.
3.83M
2.61%
+3.42M
+840.86%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
3.00M
2.05%
-10.62K
-0.35%
Aug 31, 2025
Norges Bank Investment Management (NBIM)
2.26M
1.54%
-61.02K
-2.62%
Jun 30, 2025
Invesco Capital Management LLC
2.04M
1.39%
+32.06K
+1.59%
Jun 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
Invesco Biotechnology & Genome ETF
5.49%
First Trust NASDAQ Pharmaceuticals ETF
4.45%
iShares Neuroscience and Healthcare ETF
4.25%
First Trust NYSE Arca Biotechnology Index Fund
3.53%
VanEck Biotech ETF
3.46%
Invesco Pharmaceuticals ETF
3.01%
iShares Health Innovation Active ETF
2.81%
First Trust Health Care Alphadex Fund
2.4%
ProShares Ultra Nasdaq Biotechnology
2.22%
Alger Russell Innovation ETF
2.21%
詳现ãèŠã
Invesco Biotechnology & Genome ETF
æ¯ç5.49%
First Trust NASDAQ Pharmaceuticals ETF
æ¯ç4.45%
iShares Neuroscience and Healthcare ETF
æ¯ç4.25%
First Trust NYSE Arca Biotechnology Index Fund
æ¯ç3.53%
VanEck Biotech ETF
æ¯ç3.46%
Invesco Pharmaceuticals ETF
æ¯ç3.01%
iShares Health Innovation Active ETF
æ¯ç2.81%
First Trust Health Care Alphadex Fund
æ¯ç2.4%
ProShares Ultra Nasdaq Biotechnology
æ¯ç2.22%
Alger Russell Innovation ETF
æ¯ç2.21%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
ãããã質å
Biogen Incã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îBiogen Incã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
The Vanguard Group, Inc.ã¯17.21Mæ ªãä¿æããŠãããããã¯å šäœã®11.74%ã«çžåœããŸãã
PRIMECAP Management Companyã¯15.80Mæ ªãä¿æããŠãããããã¯å šäœã®10.78%ã«çžåœããŸãã
BlackRock Institutional Trust Company, N.A.ã¯8.19Mæ ªãä¿æããŠãããããã¯å šäœã®5.59%ã«çžåœããŸãã
State Street Investment Management (US)ã¯7.47Mæ ªãä¿æããŠãããããã¯å šäœã®5.09%ã«çžåœããŸãã
Wellington Management Company, LLPã¯4.80Mæ ªãä¿æããŠãããããã¯å šäœã®3.27%ã«çžåœããŸãã
The Vanguard Group, Inc.ã¯17.21Mæ ªãä¿æããŠãããããã¯å šäœã®11.74%ã«çžåœããŸãã
PRIMECAP Management Companyã¯15.80Mæ ªãä¿æããŠãããããã¯å šäœã®10.78%ã«çžåœããŸãã
BlackRock Institutional Trust Company, N.A.ã¯8.19Mæ ªãä¿æããŠãããããã¯å šäœã®5.59%ã«çžåœããŸãã
State Street Investment Management (US)ã¯7.47Mæ ªãä¿æããŠãããããã¯å šäœã®5.09%ã«çžåœããŸãã
Wellington Management Company, LLPã¯4.80Mæ ªãä¿æããŠãããããã¯å šäœã®3.27%ã«çžåœããŸãã
Biogen Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îBiogen Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
Biogen IncïŒBIIBïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q4æç¹ã§ãBiogen Incã®æ ªåŒãä¿æããŠããæ©é¢ã¯1994瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ139.65Mã§ãå
šäœã®97.81%ãå ããŠããŸãã2025Q3ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯-0.74%å¢å ããŠããŸãã
Biogen Incã®æ倧ã®åçæºã¯äœã§ããïŒ
îFY2025Q2ã«ãããŠãMS product revenues-TYSABRIéšéãBiogen Incã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯839.80Mã§ãå
šåçã®31.74%ãå ããŠããŸãã
